With the spread of legal cannabis, researchers have more opportunities to study various cannabinoids they did not have access to before. Most recently, a cannabinoid called cannabidiphorol, or CBDP for short, was discovered in 2019 along with THCP and several other minor cannabinoids. These new additions to the growing list of cannabinoids provide us with a better understanding of the cannabis plant and its impact on our endocannabinoid systems.
According to a scientific report published in December 2019, "It is known that CBD binds with poor affinity to both CB1 and CB2 receptors. Therefore, the evaluation of the cannabimimetic activity of CBDP does not appear to be a high priority, although science can hold great surprises. Our current work is rather focused on testing its anti-inflammatory, anti-oxidant, and anti-epileptic activity, which are typical of CBD."
Because CBDP is found in such minor quantities, the progress to find out more about CBDP and other cannabinoids is slow coming. However, thanks to the federal legalization of hemp and the widespread state-level legalization of marijuana, material for research is easier to obtain.
Cannabinoid research is a new branch of science that is leading our world down a path towards possible treatments we have long been searching for. As the list of known cannabinoids becomes larger, we gain new insight into the cannabis plant and its many benefits. CBDP is just one of the newest cannabinoids to join the list, offering promising opportunities for research.